Messi and Ronaldo back AI and health startups, while Salah builds the non-tech game

Lionel Messi and Cristiano Ronaldo are betting their post-football fortunes on AI, health tech, and startups. Mohamed Salah, meanwhile, is taking a more traditional route beyond football. The split is a useful reality check for anyone who assumes star athletes all follow the same playbook. They do not. And that matters, because their choices influence where attention, deal flow, and credibility flow in early-stage markets.

Start with the headline promise: Messi and Ronaldo are actively building tech portfolios. That is not just a vibe. It signals a specific allocation direction, toward sectors that can scale quickly and attract outside funding, where founders constantly ask for validation. AI is the obvious magnet, because the category captures both hype and real industrial momentum. Health tech is the steadier sibling, often tied to durable demand, regulatory scrutiny, and complicated execution. Startups sit in the middle, where talent and timing can beat capital alone. When global celebrities like Messi and Ronaldo align with those themes, they can help an ecosystem feel more investable to other money.

Now zoom out to incentives. A tech portfolio is not only about financial upside, though it can be. It is also about network effects: credibility with founders, access to operators who can actually run companies, and a pipeline of opportunities that are harder for outsiders to see. Celebrities can accelerate attention, which can help a portfolio in fundraising and recruiting. But the tradeoff is that tech and health tech are not “set it and forget it” categories. AI and health investments tend to require ongoing diligence, governance, and staying power. Health tech in particular comes with a regulatory reality check, because companies often have to navigate safety, efficacy, data rules, and approvals before they can scale. That means investors in these spaces need operational patience and disciplined underwriting.

Regulation is also why the portfolio mix is telling. AI can move fast, but it also attracts scrutiny: how models are trained, what they do, where they are deployed, and whether they create bias or misuse. Even when an AI startup is not directly a regulated product, it can still run into legal questions around data handling and consumer impact. Health tech compounds that. The business is frequently intertwined with clinical workflows, patient privacy, and evidence standards. For boards and exec teams, that translates into a different kind of risk than, say, a traditional brand deal. The risk is not only whether revenue arrives. It is whether the product can legally and safely get to market.

So what does Salah’s “more traditional route beyond football” mean in strategic terms? It signals that not every elite athlete sees value in allocating capital the same way. Traditional investing can mean different things, but the key point is contrast: Salah is not leaning into the same AI, health tech, and startup pattern. That difference matters to decision-makers because it highlights a split in how celebrities can participate in the investment economy. Some choose high-growth tech themes where reputations can open doors fast. Others choose structures that may be more legible, less dependent on regulatory timing, and potentially easier to manage without constant product iteration.

Second-order implications show up at the board level. When a portfolio skews toward AI and health tech, the investor mindset often needs to include expertise in technical diligence and compliance pathways. Boards may end up asking tougher questions sooner: What is the model’s edge? What is the evidence of effectiveness in health use cases? What regulatory milestones must happen, and by when? If the portfolio is celebrity-supported, companies can also face pressure to move quickly, because attention can create momentum that can outrun readiness. The winners tend to be the teams that channel that attention into governance, not just marketing.

For founders and executives, the broader takeaway is about signaling. If Messi and Ronaldo are underwriting AI, health tech, and startups, they are telling the market what kind of ventures they believe deserve capital and attention. That can pull forward conversations with other angel networks, strategic investors, and venture firms that monitor celebrity participation as a shorthand for “credible interest.” Meanwhile, Salah’s traditional approach acts like a counter-signal. It suggests that even with extreme star power, there is no universal rule that tech is the only path to post-sports influence.

In short, the world of athlete investing is diversifying in public, and that is strategically important. AI and health tech are sectors where regulatory framing, execution discipline, and long-cycle patience can make or break outcomes. A traditional route can reduce some of that complexity, even if it caps certain types of upside. If you are an executive, an investor, or a board member tracking where capital and credibility flow, this split is a reminder: where the money goes depends on more than hype. It depends on incentives, governance capacity, and how comfortable each player is with regulated timelines and technical risk.